switching from oral to injectable semaglutide For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for weight management as a once-weekly subcutaneous injection. In a previous trial, at a dose of 50 mg Can a patient transition from

Ozempic (semaglutide) functions as a glucagon-like peptide-1 (GLP-1) receptor agonist that slows gastric emptying, increases satiety signals, and improves insulin sensitivity without direct stimulant effects

In the direct-to-consumer market, however, this approach pits two value propositions against each other: helping patients build habits that allow them to discontinue GLP-1s versus encouraging long-term use through maintenance dosing

For most people, the biggest improvements in performance and longevity still come from: Consistent resistance training Cardiovascular fitness High quality sleep Adequate protein intake Metabolic health Peptides may have a role in selected individuals

Psychiatry 29 , 25872598 (2024)